SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

4519 (4519) News

Follow 4519 (4519) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 4519 Asset market Sector Markets 90 days 5 Updated Oct 27, 2026, 08:54 AM UTC Open live news feed
M Chugai Pharmaceutical Nine-Month Profit Rises to JPY375.302 Billion Chugai Pharmaceutical reported nine-month earnings of JPY375.302 billion, or JPY228.07 per share, compared with JPY305.602 billion and JPY185.70 per share a year earlier. EARNINGS | Oct 27, 2026, 08:54 AM UTC M Chugai Pharmaceutical 9-Month Net Y375.30B vs. Y305.60B Chugai Pharmaceutical reported net income of Y375.30B for nine months, versus Y305.60B. EARNINGS | Oct 27, 2026, 08:00 AM UTC L Chugai Pharmaceutical's Pipeline Looking Increasingly Thin — Market Talk Chugai Pharmaceutical's mid-to late-stage pipeline is looking increasingly thin, Jefferies analysts say in a note. Roche has discontinued development of GYM329 for obesity and returned the rights to Chugai. Investors hav NEWS | Sep 29, 2026, 02:57 AM UTC L Roche Halts Development of Obesity Drug Candidate By Adria CalatayudRoche Holding said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn't hit internal targets.The Swiss drugmaker said it returned rights to th NEWS | Sep 28, 2026, 12:34 PM UTC L Chugai Pharmaceutical Co Ltd - Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA Chugai Pharmaceutical Co Ltd TSE:4519 NEWS | Sep 28, 2026, 07:04 AM UTC